Sequential Extracorporeal Blood Purification Is Associated with Prolonged Survival among ICU Patients with COVID-19 and Confirmed Bacterial Superinfection

Author:

Premuzic VedranORCID,Situm IvanORCID,Lovric DanielORCID,Erceg AnteORCID,Karmelic DoraORCID,Mogus Mate,Jurjevic Matija,Nedeljkovic Vanja,Mazar Mirabel,Mihaljevic Slobodan,Villa Gianluca,Ronco Claudio

Abstract

<b><i>Introduction:</i></b> This study investigates the impact of sequential extracorporeal treatments with oXiris<sup>®</sup> or CytoSorb<sup>®</sup> plus Seraph-100<sup>®</sup> on the clinical and laboratory parameters of critically ill COVID-19 patients with bacterial superinfection. <b><i>Methods:</i></b> Patients admitted to the intensive care unit with COVID-19, bacterial superinfection, and undergoing blood purification (BP) were enrolled in this prospective, single-center, observational study. “standard BP” with oXiris<sup>®</sup> or CytoSorb<sup>®</sup> were used in 35 COVID-19 patients with bacterial infection. Seraph-100<sup>®</sup> was added in 33 patients when available serially in the same oXiris<sup>®</sup> circuit or as sequential treatment with CytoSorb<sup>®</sup> as a sequential BP. <b><i>Results:</i></b> A significant reduction in SOFA score 3 days after treatment was observed in patients undergoing sequential BP (11.3 vs. 8.17, <i>p</i> &lt; 0.01) compared to those undergoing “standard BP” (11.0 vs. 10.3, <i>p</i> &gt; 0.05). The difference between the observed and expected mortality rate based on APACHE IV was greater in the sequential BP group (42.4% vs. 81.7%, <i>p</i> &lt; 0.001) than the “standard BP” (74.2% vs. 81.7%, <i>p</i> &gt; 0.05). Patients treated with sequential BP had a longer survival than those treated with “standard BP” (22.4 vs. 18.7 months; <i>p</i> &lt; 0.001). <b><i>Conclusions:</i></b> The sequential approach may enhance the positive effect of BP on organ dysfunction among critically ill patients with COVID-19 and bacterial superinfection.

Publisher

S. Karger AG

Subject

Nephrology,Hematology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3